Toronto, Ontario – September 29, 2022, Theralase® Technologies Inc. (“Theralase” or “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs“) and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 3,157,059 share purchase warrants, all of which are exercisable at $0.50 per share (collectively, the “Warrants“). The Warrants were issued on October 3, 2018 pursuant to a private placement involving the issuance of 3,157,059 units of the Company. The Warrants were previously amended to extend the original expiry date of October 3, 2020 to October 3, 2022. Now, the Company proposes to extend the amended expiry date of October 3, 2022 to October 3, 2023.  All other terms and conditions of the Warrants will remain unchanged. The Warrant expiry date extension is subject to final acceptance by the … Read More

Toronto, Ontario – September 22, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that it has closed a non-brokered private placement offering (“Offering”) of units (“Units”). On closing, the Corporation issued an aggregate of 10,000,000 Units at a price of $0.25 per Unit for aggregate gross proceeds of approximately $2,500,000. Each Unit consisted of one common share of the Company (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $0.35 per share for a period of 24 months following the date of issuance.  In connection with the Offering, the Company paid a finder’s fee of $10,167 in cash and … Read More

Toronto, Ontario – August 29, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s unaudited 2Q2022 condensed interim consolidated Financial Statements (“Financial Statements”). Financial Highlights: For the six-month period ended June 30th: Audited Consolidated Statements of Operations             In Canadian Dollars     2022 2021 % Change  Revenue       Canada 426,990     384,154 11% United States 125,452        32,656  284% International 0        13,189  -100% Total Revenue 552,442 429,999 28%         Cost of Sales 271,656 230,370 18% Gross Margin 280,786 199,629 41% Gross Margin as a percentage of sales 51% 46%           Operating Expenses       Selling Expenses 167,139 197,400 -15% Administrative Expenses 734,081 802,271 -8% Research and Development Expenses – CLT Division 105,353 88,141 20% Research … Read More

Toronto, Ontario – June 28, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that the Company has expanded its Intellectual Property (“IP”) portfolio. Theralase® has recently been granted a Brazilian patent for, “Metal-Based Thiopene Photodynamic Compounds and their Use” (“Patent”). The patent advances Theralase’s intellectual property portfolio internationally strengthening the patent portfolio around the Anti-Cancer Technology (“ACT”) platform. The patent encompasses an extensive library of PDCs, including Theralase’s lead PDC, TLD-1433, approved by Health Canada to be evaluated in a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”). The Mechanism of Action (“MOA”) of the patented Theralase® PDCs involves selective localization of the PDC inside the … Read More

Toronto, Ontario – June 24, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that Theralase®’s research, published in Translational Biophotonics (“TBIO”), is one of the top 10 most downloaded papers in TBIO, amongst work published between January 1, 2019 to December 31, 2020.  According to the TBIO’s website, TBIO is an international peer-reviewed, open access journal dedicated to bridging the gap in translating medical photonic research into clinical practice. TBIO serves as a platform for translating photonic methods and technologies in all medical areas to solve unmet medical needs in diagnosis and therapy. The symbiosis between photonics and medicine serves as the bridge in integrating translational research into clinical practice. The Theralase® sponsored research entitled, “Evaluation of a … Read More

Toronto, Ontario – June 21, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce that Theralase®’s Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) has been peer reviewed and published in the European Urology Open Science (“EUOS”) Journal, Volume 41, July 2022. According to EUOS’s website, EUOS is dedicated to the publication of high quality, innovative research that will benefit patients with urological conditions. EUOS covers research in the urological field, including clinical, basic and translational research. The publication can be accessed online at no charge at:  https://www.sciencedirect.com/science/article/pii/S2666168322005900 The publication states, “Despite efforts to bring new treatment strategies forward for Bacillus Calmette Guérin (“BCG”)-Unresponsive NMIBC, a clear consensus for a standard treatment other than radical cystectomy has yet to … Read More

Toronto, Ontario – May 30, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s unaudited 1Q2022 condensed interim consolidated Financial Statements (“Financial Statements”). Financial Highlights: For the three- month period ended March 31st: Audited Consolidated Statements of Operations             In Canadian Dollars     2022 2021 % Change  Revenue       Canada 179,145 104,406 72% United States 32,517         20,377 60% Total Revenue 211,662 124,783 70%         Cost of Sales 120,430 74,463 62% Gross Margin 91,232 50,320 81% Gross Margin as a percentage of sales 43% 40%           Operating Expenses       Selling Expenses 87,640 95,780 -8% Administrative Expenses 418,087 418,454 1% Research and Development Expenses – CLT Division 72,832 54,616 33% Research and Development Expenses … Read More

Toronto, Ontario – April 29, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2021 financial statements. Financial Highlights: For the years ended December 31st: Audited Consolidated Statements of Operations             In Canadian Dollars    2021 2020 % Change   Revenue       Canada 697,727 815,159 -14% United States 69,725 87,923 -21% International 13,189 26,040 -49% Total Revenue 780,641 929,122 -16%         Cost of Sales 470,698 659,442 -29% Gross Margin 309,943 269,680 15% Gross Margin as a percentage of sales 40% 29%           Operating Expenses       Selling Expenses 363,886 447,882 -19% Administrative Expenses 1,562,867 2,070,261 -25% Research and Development Expenses – CLT Division 308,708 … Read More

Toronto, Ontario – April 5, 2022, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) 1 and their associated drug formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, has provided an update on the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC“) Clinical Study (“Study II”). As previously announced, Theralase® successfully completed a Phase Ib NMIBC Clinical Study (“Study I”), which enrolled and provided the primary study treatment, at the therapeutic dose, for 3 patients.  To date, Study II has enrolled and provided the primary study treatment for 35 patients, which when combined with the Study I data, leads to a total of 38 patients, who have received at a minimum, the primary study treatment. Study II Clinical Study Data: Assessment (Days) Complete Response (“CR”) … Read More

Toronto, Ontario – February 7, 2022, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds1 (“PDC”) and their associated drug formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 (“COVID-19”) vaccine.  In August 2020, Theralase® reported that it had executed a Sponsored Research Agreement (“SRA”) with the University of Manitoba (“UM”) medical microbiology department to commence research and development of a Canadian-made vaccine, utilizing Theralase®’s patented and proprietary PDC, TLD-1433.  In November 2020, Theralase® reported that, UM was able to demonstrate that TLD-1433 was effective in the rapid destruction of various viruses, including: H1N1 Influenza, Zika and a Biological Safety Level (“BSL”)-2 coronavirus at low nanomolar (“nM”) concentrations.  All these enveloped viruses are similar in structure to … Read More